Cutaneous/Mucocutaneous Leishmaniasis Treatment for Wound Healing: Classical versus New Treatment Approaches Severino, Patricia Clares Naveros, Beatriz Cutaneous leishmaniasis (CL) Mucocutaneous leishmaniasis (ML) Topical formulations Drug delivery Nanomaterials Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can range from a localized lesion (with a spontaneous healing process) to cases that progress to a generalized systemic disease with a risk of death. The treatment of leishmaniasis is complex since most of the available drugs show high toxicity. The development of an effective topical drug formulation for CL and ML treatment offers advantages as it will improve patient’s compliance to the therapy given the possibility for self-administration, as well as overcoming the first pass metabolism and the high costs of currently available alternatives. The most common dosage forms include solid formulations, such as membranes and semi-solid formulations (e.g., ointments, creams, gels, and pastes). Topical treatment has been used as a new route of administration for conventional drugs against leishmaniasis and its combinations, as well as to exploit new substances. In this review, we discuss the advantages and limitations of using topical drug delivery for the treatment of these two forms of leishmaniasis and the relevance of combining this approach with other pharmaceutical dosage forms. Emphasis will also be given to the use of nanomaterials for site-specific delivery. 2023-01-24T07:46:55Z 2023-01-24T07:46:55Z 2022-10-17 info:eu-repo/semantics/article Severino, P... [et al.]. Cutaneous/Mucocutaneous Leishmaniasis Treatment forWound Healing: Classical versus New Treatment Approaches. Microbiol. Res. 2022, 13, 836–852. [https://doi.org/10.3390/microbiolres13040059] https://hdl.handle.net/10481/79281 10.3390/microbiolres13040059 eng http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional MDPI